March 31, 2021
“This is a precautionary step.”
The AstraZeneca vaccine was created in partnership with Oxford University.
- The concern: abnormal blood clotting.
- After administering more than 100,000 doses Ireland suspended use based on news out of Norway, where abnormal blood clotting reports emerged in several younger recipients of the vaccine.
- From The Associated Press: “The company said that a review of safety data of more than 17 million people who have received the AstraZeneca vaccine in the European Union and the U.K. ‘has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country.’”
- Why It Matters: The AstraZeneca vaccine remains one of the earliest COVID-19 vaccines used and the company is expected to apply for its emergency use authorization in the U.S. within weeks. However, the list of countries to suspend or delay use continues to grow.
Here’s a good read on the topic: CLICK HERE
by Jenna Lee,
